Ivabradine for treating chronic heart failure

so cannot be shown here. However, the ERG emphasised that these analyses are speculative and based on subgroups of subgroups and should be interpreted with caution. Cost-effectiveness evidence 3.23 In a systematic review of the literature, the manufacturer did not identify any study on the cost effectiveness of ivabradine for treating chronic heart failure. No cost-effectiveness data were presented for the main SHIFT population, and so the economic evaluation carried out by the manufacturer was based only on the post hoc subgroup of patients from SHIFT with a baseline heart rate of 75 bpm or more. The manufacturer stated that this subgroup reflected the marketing authorisation for ivabradine; that is, people with chronic heart failure NYHA class 2 to 4 with systolic dysfunction, in sinus rhythm and whose heart rate is 75 bpm or more, who are being treated with ivabradine in combination with standard therapy including beta-blockers, or for whom beta-blockers are contraindicated or not tolerated. 3.24 The manufacturer developed a Markov cohort model consisting of 2 states (alive and dead). The difference in quality of life of patients was captured according to NYHA class in the 'alive' state of the model without modelling the NYHA classes as separate
